Affimed has terminated its phase 1 bispecific T-cell engager program seven months after the FDA hit it with a clinical hold. The action shifts Affimed’s focus to innate cell engagers that it plans to combine with other modalities to treat cancers.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,